Depo-subq provera 104 vs. Femcon fe: side effect and effectiveness comparison - a phase IV clinical study

Summary:

We compare the side effects and drug effectiveness of Depo-subq provera 104 and Femcon fe. The phase IV clinical study is created by eHealthMe based on reports (from sources including the FDA) of 71,482 people who take Depo-subq provera 104 and Femcon fe, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 01, 2022

71,482 people who take Depo-subq provera 104 and Femcon fe are studied.


What is Depo-subq provera 104?

Depo-subq provera 104 has active ingredients of medroxyprogesterone acetate. It is often used in birth control. eHealthMe is studying from 301 Depo-subq provera 104 users for its effectiveness, alternative drugs and more.

What is Femcon fe?

Femcon fe has active ingredients of ethinyl estradiol; norethindrone. It is often used in birth control. eHealthMe is studying from 241 Femcon fe users for its effectiveness, alternative drugs and more.

Number of reports submitted per year:

Depo-subq provera 104 vs Femcon fe drug comparison reports.

Drugs being compared in this study:

  • Depo-Subq Provera 104 (medroxyprogesterone acetate)
  • Femcon Fe (ethinyl estradiol; norethindrone)

Most common side effects of the drugs, overall:

Click here to view

Most common side effects of the drugs, in long term (1+ years) use:

Click here to view

Drug effectiveness:

Depo-Subq Provera 104:
  • not at all: 4.21 %
  • somewhat: 6.62 %
  • moderate: 12.2 %
  • high: 32.81 %
  • very high: 44.16 %
Femcon Fe:
  • not at all: 0.48 %
  • somewhat: 4.29 %
  • moderate: 14.76 %
  • high: 37.62 %
  • very high: 42.86 %

Want to compare Depo-subq provera 104 with Femcon fe?

Personalize this study to your gender and age (0-99+).

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of:

Common Depo-subq provera 104 side effects:

How the study uses the data?

The study is based on medroxyprogesterone acetate and ethinyl estradiol; norethindrone (the active ingredients of Depo-subq provera 104 and Femcon fe, respectively). Other drugs that have the same active ingredients (e.g. generic drugs or brand names) are also considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: